

Alexander Danser

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4814436/alexander-danser-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

318
papers

11,462
citations

58
h-index

92
g-index

336
ext. papers

13,222
ext. citations

6.4
avg, IF

6.61
L-index

#	Paper	IF	Citations
318	Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.. <i>Lancet Neurology, The</i> , 2022 ,	24.1	7
317	Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 115-124	6.7	1
316	Effect of Sunitinib Treatment on Skin Sodium Accumulation in Patients With Renal Cancer: a Pilot Study.. <i>Hypertension</i> , 2022 , HYPERTENSIONAHA12219079	8.5	0
315	The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.. <i>Kidney International Reports</i> , 2022 , 7, 1084-1092	4.1	0
314	Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).. <i>Hypertension</i> , 2022 , HYPERTENSIONAHA12219070	8.5	1
313	The relation of RAAS activity and endothelin-1 levels to coronary atherosclerotic burden and microvascular dysfunction in chest pain patients.. <i>Atherosclerosis</i> , 2022 , 347, 47-54	3.1	1
312	Transplacental Zika virus transmission in ex vivo perfused human placentas.. <i>PLoS Neglected Tropical Diseases</i> , 2022 , 16, e0010359	4.8	0
311	Transforming Growth Factor- β and the Renin-Angiotensin System in Syndromic Thoracic Aortic Aneurysms: Implications for Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 1233-1252	3.9	9
310	Reduced nitric oxide bioavailability impairs myocardial oxygen balance during exercise in swine with multiple risk factors. <i>Basic Research in Cardiology</i> , 2021 , 116, 50	11.8	2
309	The Effects of Acute and Chronic Selective Phosphodiesterase 1 Inhibition on Smooth Muscle Cell-Associated Aging Features.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 818355	5.6	0
308	Sex Differences in Response to Triptans: A Systematic Review and Meta-analysis. <i>Neurology</i> , 2021 , 96, 162-170	6.5	10
307	Corpus luteum number and the maternal renin-angiotensin-aldosterone system as determinants of utero-placental (vascular) development: the Rotterdam Periconceptual Cohort. <i>Reproductive Biology and Endocrinology</i> , 2021 , 19, 164	5	2
306	The Function of the Kynurenine Pathway in the Placenta: A Novel Pharmacotherapeutic Target?. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	3
305	Reduced nitric oxide bioavailability impairs myocardial oxygen balance during exercise in swine with multiple risk factors. <i>Basic Research in Cardiology</i> , 2021 , 116, 50	11.8	2
304	Perivascular adipose tissue in vascular function: does locally synthesized angiotensinogen play a role?. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 78,	3.1	2
303	In Vivo Renin Activity Imaging in the Kidney of Progeroid Mutant Mice. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
302	A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity. <i>Journal of Hypertension</i> , 2021 ,	1.9	3

301	Comment on: The sFlt-1 to PlGF Ratio in Pregnant Women with Rheumatoid Arthritis: Impact of Disease Activity and Sulfasalazine Use. Reply. <i>Rheumatology</i> , 2021 ,	3.9	
300	Effect of sodium bicarbonate supplementation on the renin-angiotensin system in patients with chronic kidney disease and acidosis: a randomized clinical trial. <i>Journal of Nephrology</i> , 2021 , 34, 1737-1745	4.8	3
299	Thrombomodulin is upregulated in the kidneys of women with pre-eclampsia. <i>Scientific Reports</i> , 2021 , 11, 5692	4.9	3
298	Functional tests to guide management in an adult with loss of function of type-1 angiotensin II receptor. <i>Pediatric Nephrology</i> , 2021 , 36, 2731-2737	3.2	
297	Angiogenic markers during preeclampsia: Are they associated with hypertension 1 year postpartum?. <i>Pregnancy Hypertension</i> , 2021 , 23, 116-122	2.6	1
296	Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. <i>Circulation Research</i> , 2021 , 128, 1040-1061	15.7	14
295	Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, F654-F668	4.3	2
294	Brain angiotensin suppression in the DOCA-salt model: reversal by angiotensinogen small interfering RNA?. <i>Clinical Science</i> , 2021 , 135, 885-886	6.5	1
293	The sFlt-1 to PlGF Ratio in Pregnant Women with Rheumatoid Arthritis: Impact of Disease Activity and Sulfasalazine Use. <i>Rheumatology</i> , 2021 ,	3.9	3
292	Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease. <i>Hypertension</i> , 2021 , 77, 1600-1612	8.5	4
291	Selective Phosphodiesterase 1 Inhibition Ameliorates Vascular Function, Reduces Inflammatory Response, and Lowers Blood Pressure in Aging Animals. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 378, 173-183	4.7	2
290	Meta-analysis of epigenome-wide association studies of carotid intima-media thickness. <i>European Journal of Epidemiology</i> , 2021 , 36, 1143-1155	12.1	4
289	Prorenin periconceptionally and in pregnancy: Does it have a physiological role?. <i>Molecular and Cellular Endocrinology</i> , 2021 , 529, 111281	4.4	0
288	Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?. <i>Clinical Science</i> , 2021 , 135, 1649-1668	6.5	3
287	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 68-78	12.3	19
286	Human kidney organoids produce functional renin. <i>Kidney International</i> , 2021 , 99, 134-147	9.9	12
285	Prorenin periconceptionally and in pregnancy: Does it have a physiological role?. <i>Molecular and Cellular Endocrinology</i> , 2021 , 522, 111118	4.4	3
284	Fifty years of research on the brain renin-angiotensin system: what have we learned?. <i>Clinical Science</i> , 2021 , 135, 1727-1731	6.5	2

283	Megalyn, Proton Pump Inhibitors and the Renin-Angiotensin System in Healthy and Pre-Eclamptic Placentas. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
282	Vascular Ageing Features Caused by Selective DNA Damage in Smooth Muscle Cell. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 2308317	6.7	3
281	Accurate Prediction of Total PlGF (Placental Growth Factor) From Free PlGF and sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1): Evidence for Markedly Elevated PlGF Levels in Women With Acute Fatty Liver of Pregnancy. <i>Hypertension</i> , 2021 , 78, 489-498	8.5	2
280	Cardiac Angiotensin II Is Generated Locally by ACE and Not Chymase. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 540-541	15.1	0
279	Renal Angiotensinogen Is Predominantly Liver Derived in Nonhuman Primates. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 2851-2853	9.4	3
278	No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension. <i>Clinical Science</i> , 2021 , 135, 259-274	6.5	12
277	(Pro)renin Receptor Inhibition Reduces Plasma Cholesterol and Triglycerides but Does Not Attenuate Atherosclerosis in Atherosclerotic Mice.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 725203 ⁵⁻⁴		
276	Therapeutic Potential of Sunitinib in Ameliorating Endothelial Dysfunction in Type 2 Diabetic Rats.. <i>Pharmacology</i> , 2021 , 1-7	2.3	
275	The Placental Innate Immune System Is Altered in Early-Onset Preeclampsia, but Not in Late-Onset Preeclampsia.. <i>Frontiers in Immunology</i> , 2021 , 12, 780043	8.4	1
274	Cardiac and Vascular β Adrenoceptors in Congestive Heart Failure: A Systematic Review. <i>Cells</i> , 2020 , 9,	7.9	4
273	Effect of high-salt diet on blood pressure and body fluid composition in patients with type 1 diabetes: randomized controlled intervention trial. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	3
272	l-Tryptophan-Induced Vasodilation Is Enhanced in Preeclampsia: Studies on Its Uptake and Metabolism in the Human Placenta. <i>Hypertension</i> , 2020 , 76, 184-194	8.5	10
271	Megalyn: a Novel Determinant of Renin-Angiotensin System Activity in the Kidney?. <i>Current Hypertension Reports</i> , 2020 , 22, 30	4.7	6
270	Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. <i>Hypertension</i> , 2020 , 75, 1382-1385	8.5	323
269	Chronic Sildenafil Treatment Improves Vasomotor Function in a Mouse Model of Accelerated Aging. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
268	Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 835-837	5.3	34
267	Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice. <i>Annals of Neurology</i> , 2020 , 88, 771-784	9.4	34
266	Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. <i>Pain</i> , 2020 , 161, 1092-1099	8	33

265	Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 319, F729-F745	4.3	13
264	MicroRNA-148a regulates low-density lipoprotein metabolism by repressing the (pro)renin receptor. <i>PLoS ONE</i> , 2020 , 15, e0225356	3.7	3
263	SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. <i>Clinical Science</i> , 2020 , 134, 3107-3118	6.5	4
262	Local endothelial DNA repair deficiency causes aging-resembling endothelial-specific dysfunction. <i>Clinical Science</i> , 2020 , 134, 727-746	6.5	9
261	The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020 , 127, 67-80	3.1	16
260	Targeting angiotensinogen with RNA-based therapeutics. <i>Current Opinion in Nephrology and Hypertension</i> , 2020 , 29, 180-189	3.5	10
259	Transfer and Vascular Effect of Endothelin Receptor Antagonists in the Human Placenta. <i>Hypertension</i> , 2020 , 75, 877-884	8.5	7
258	Simultaneous quantification of ambrisentan, macitentan and sitaxentan in human plasma using UPLC-MS/MS. <i>Biomedical Chromatography</i> , 2020 , 34, e4787	1.7	2
257	Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury. <i>Journal of Hypertension</i> , 2020 , 38, 755-764	1.9	12
256	PAPP-A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia. <i>Journal of the American Heart Association</i> , 2020 , 9, e018219	6	4
255	The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 1	3.9	3
254	Effects of Renin-Angiotensin Inhibition on ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Protease Serine 2) Expression: Insights Into COVID-19. <i>Hypertension</i> , 2020 , 76, e29-e30	8.5	25
253	Determinants of Maternal Renin-Angiotensin-Aldosterone-System Activation in Early Pregnancy: Insights From 2 Cohorts. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	11
252	Nitric Oxide-cGMP Signaling in Hypertension: Current and Future Options for Pharmacotherapy. <i>Hypertension</i> , 2020 , 76, 1055-1068	8.5	16
251	Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimpiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. <i>Diabetes Care</i> , 2020 , 43, 2889-2893	14.6	6
250	The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. <i>Kidney International</i> , 2020 , 97, 202-212	9.9	117
249	Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. <i>Cardiovascular Research</i> , 2020 , 116, 1779-1790	9.9	13
248	Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition?. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020 , 127, 132-141	3.1	11

247	A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 650-662	12.7	15
246	Megalin: A Novel Endocytic Receptor for Prorenin and Renin. <i>Hypertension</i> , 2020 , 75, 1242-1250	8.5	14
245	Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets. <i>Frontiers in Physiology</i> , 2019 , 10, 1108	4.6	19
244	Placental effects and transfer of sildenafil in healthy and preeclamptic conditions. <i>EBioMedicine</i> , 2019 , 45, 447-455	8.8	21
243	Endothelin receptor antagonism during preeclampsia: a matter of timing?. <i>Clinical Science</i> , 2019 , 133, 1341-1352	6.5	5
242	The renin-angiotensin-aldosterone system and its therapeutic targets. <i>Experimental Eye Research</i> , 2019 , 186, 107680	3.7	69
241	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	37
240	Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models. <i>Cephalalgia</i> , 2019 , 39, 1421-1434	6.1	15
239	Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. <i>Hypertension</i> , 2019 , 73, 1249-1257	8.5	40
238	Ultrafine particles and ozone perturb norepinephrine clearance rather than centrally generated sympathetic activity in humans. <i>Scientific Reports</i> , 2019 , 9, 3641	4.9	8
237	Dissecting the association of autophagy-related genes with cardiovascular diseases and intermediate vascular traits: A population-based approach. <i>PLoS ONE</i> , 2019 , 14, e0214137	3.7	9
236	Revisiting the Brain Renin-Angiotensin System-Focus on Novel Therapies. <i>Current Hypertension Reports</i> , 2019 , 21, 28	4.7	33
235	Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension. <i>Cardiovascular Research</i> , 2019 , 115, 904-914	9.9	33
234	Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin. <i>Journal of Physiology</i> , 2019 , 597, 1157-1173	3.9	15
233	Intervening with the Nitric Oxide Pathway to Alleviate Pulmonary Hypertension in Pulmonary Vein Stenosis. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	4
232	The MOVD/EDH 2019. <i>European Heart Journal</i> , 2019 , 40, 2385-2386	9.5	
231	The role of DNA methylation and histone modifications in blood pressure: a systematic review. <i>Journal of Human Hypertension</i> , 2019 , 33, 703-715	2.6	13
230	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. <i>Pharmacological Reviews</i> , 2019 , 71, 539-570	22.5	146

229	Letter to the Editor regarding "A microanalytical capillary electrophoresis mass spectrometry assay for quantifying angiotensin peptides in the brain". <i>Analytical and Bioanalytical Chemistry</i> , 2019 , 411, 8163-8164	4.4	3
228	Human Placental Vascular Reactivity in Health and Disease: Implications for the Treatment of Pre-eclampsia. <i>Current Pharmaceutical Design</i> , 2019 , 25, 505-527	3.3	10
227	Vasoresponsiveness in patients with heart failure (VASOR): protocol for a prospective observational study. <i>Journal of Cardiothoracic Surgery</i> , 2019 , 14, 200	1.6	
226	Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 150-155	9.4	25
225	Trigeminovascular calcitonin gene-related peptide function in Cacna1a R192Q-mutated knock-in mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 718-729	7.3	8
224	Nephrilysin inhibition and endothelin-1 elevation: Focus on the kidney. <i>European Journal of Pharmacology</i> , 2018 , 824, 128-132	5.3	5
223	Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. <i>Cardiovascular Research</i> , 2018 , 114, 954-964	9.9	96
222	Reproducibility and agreement of different non-invasive methods of endothelial function assessment. <i>Microvascular Research</i> , 2018 , 117, 50-56	3.7	13
221	Autoantibodies against angiotensin and adrenergic receptors: more than a biomarker?. <i>Clinical Science</i> , 2018 , 132, 127-130	6.5	4
220	(Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis. <i>Circulation Research</i> , 2018 , 122, 730-741	15.7	29
219	Angiotensin generation in the brain: a re-evaluation. <i>Clinical Science</i> , 2018 , 132, 839-850	6.5	25
218	The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies. <i>Pregnancy Hypertension</i> , 2018 , 14, 222-227	2.6	16
217	Endothelium-derived hyperpolarizing factor and protein kinase G activation: HO versus S-nitrosothiols. <i>European Journal of Pharmacology</i> , 2018 , 827, 112-116	5.3	3
216	Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, F873-F878	4.3	19
215	Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018 , 51, 751-757	5.8	22
214	Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients. <i>Journal of the American Society of Hypertension</i> , 2018 , 12, e1-e7		1
213	The macula densa prorenin receptor is essential in renin release and blood pressure control. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 315, F521-F534	4.3	23
212	Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients. <i>Hypertension</i> , 2018 , 72, 314-322	8.5	6

211	The effect of bioresorbable vascular scaffold implantation on distal coronary endothelial function in dyslipidemic swine with and without diabetes. <i>International Journal of Cardiology</i> , 2018 , 252, 44-51	3.2	3
210	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 462-471	1.9	8
209	Sunitinib-induced blood pressure rise does not involve aldosterone: observations in a patient after bilateral adrenalectomy. <i>Journal of Hypertension</i> , 2018 , 36, 2279-2280	1.9	5
208	Pulmonary microvascular remodeling in chronic thrombo-embolic pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018 , 315, L951-L964	5.8	9
207	Changes in the nitric oxide pathway of the pulmonary vasculature after exposure to hypoxia in swine model of neonatal pulmonary vascular disease. <i>Physiological Reports</i> , 2018 , 6, e13889	2.6	4
206	Focus on increased serum angiotensin-converting enzyme level: From granulomatous diseases to genetic mutations. <i>Clinical Biochemistry</i> , 2018 , 59, 1-8	3.5	13
205	Phytoestrogen supplementation and body composition in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials. <i>Maturitas</i> , 2018 , 115, 74-83	5	30
204	Brain Renin-Angiotensin System: Does It Exist?. <i>Hypertension</i> , 2017 , 69, 1136-1144	8.5	51
203	Transcriptome Analysis of Human Reninomas as an Approach to Understanding Juxtaglomerular Cell Biology. <i>Hypertension</i> , 2017 , 69, 1145-1155	8.5	5
202	Do prorenin-synthesizing cells release active, OpenProrenin?. <i>Journal of Hypertension</i> , 2017 , 35, 330-337	9	4
201	Recent Advances in Angiotensin Research. <i>Hypertension</i> , 2017 , 69, 994-999	8.5	14
200	Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1669-1680	6.7	37
199	Dietary restriction but not angiotensin II type 1 receptor blockade improves DNA damage-related vasodilator dysfunction in rapidly aging mice. <i>Clinical Science</i> , 2017 , 131, 1941-1953	6.5	11
198	(Pro)renin receptor as a therapeutic target for the treatment of cardiovascular diseases?. <i>Pharmacological Research</i> , 2017 , 125, 48-56	10.2	13
197	Juxtaglomerular Cell Phenotypic Plasticity. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 231-242	2.9	10
196	Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition. <i>Hypertension</i> , 2017 , 70, 220-226	8.5	50
195	Altered purinergic signaling in uridine adenosine tetraphosphate-induced coronary relaxation in swine with metabolic derangement. <i>Purinergic Signalling</i> , 2017 , 13, 319-329	3.8	11
194	Salt Sensitivity of Angiogenesis Inhibition-Induced Blood Pressure Rise: Role of Interstitial Sodium Accumulation?. <i>Hypertension</i> , 2017 , 69, 919-926	8.5	28

193	Identifying treatment response to antihypertensives in patients with obesity-related hypertension. <i>Clinical Hypertension</i> , 2017 , 23, 20	4.8	3
192	Sex differences in pulmonary vascular control: focus on the nitric oxide pathway. <i>Physiological Reports</i> , 2017 , 5, e13200	2.6	3
191	Soluble (pro)renin receptor in preeclampsia and diabetic pregnancies. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 644-652		9
190	Angiogenic Markers Predict Pregnancy Complications and Prolongation in Preeclampsia: Continuous Versus Cutoff Values. <i>Hypertension</i> , 2017 , 70, 1025-1033	8.5	28
189	Low Soluble Fms-Like Tyrosine Kinase-1, Endoglin, and Endothelin-1 Levels in Women With Confirmed or Suspected Preeclampsia Using Proton Pump Inhibitors. <i>Hypertension</i> , 2017 , 70, 594-600	8.5	29
188	Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 488-497		1
187	Urinary renin-angiotensin markers in polycystic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 313, F874-F881	4.3	13
186	From ARB to ARNI in Cardiovascular Control. <i>Current Hypertension Reports</i> , 2016 , 18, 86	4.7	9
185	Reply. <i>Journal of Hypertension</i> , 2016 , 34, 1654-5	1.9	
184	Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition. <i>Hypertension</i> , 2016 , 68, 17-23	8.5	14
183	The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016 , 10, 282-93	3.4	61
182	Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 914-21	4.3	11
181	Changes in Coronary Blood Flow After Acute Myocardial Infarction: Insights From a Patient Study and an Experimental Porcine Model. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 602-13	5	31
180	On the Origin of Urinary Renin: A Translational Approach. <i>Hypertension</i> , 2016 , 67, 927-33	8.5	30
179	Endothelin-1 and antiangiogenesis. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016 , 310, R230-4	3.2	29
178	Identification of the (Pro)renin Receptor as a Novel Regulator of Low-Density Lipoprotein Metabolism. <i>Circulation Research</i> , 2016 , 118, 222-9	15.7	29
177	Beneficial Effects of Combined AT1 Receptor/Nepriylsin Inhibition (ARNI) Versus AT1 Receptor Blockade Alone in the Diabetic Eye 2016 , 57, 6722-6730		9
176	DNA Damage: A Main Determinant of Vascular Aging. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	47

175	Colocalization of the (Pro)renin Receptor/Atp6ap2 with H ⁺ -ATPases in Mouse Kidney but Prorenin Does Not Acutely Regulate Intercalated Cell H ⁺ -ATPase Activity. <i>PLoS ONE</i> , 2016 , 11, e0147831	3.7	21
174	AT1-receptor blockade, but not renin inhibition, reduces aneurysm growth and cardiac failure in fibulin-4 mice. <i>Journal of Hypertension</i> , 2016 , 34, 654-65	1.9	10
173	Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren. <i>Journal of Hypertension</i> , 2016 , 34, 935-41	1.9	1
172	Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016 , 311, H1339-H1351	5.2	37
171	The sFlt-1/PlGF ratio associates with prolongation and adverse outcome of pregnancy in women with (suspected) preeclampsia: analysis of a high-risk cohort. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016 , 199, 121-6	2.4	15
170	Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. <i>Diabetologia</i> , 2016 , 59, 1412-1421	10.3	74
169	Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENetic (PERGENE) Risk Model. <i>Journal of the American Heart Association</i> , 2016 , 5, e002688	6	10
168	Response by Danser and van den Meiracker to Letter by Zhou and Zhou Regarding Article, "Hypertension: Renin-Angiotensin-Aldosterone System Alterations". <i>Circulation Research</i> , 2016 , 119, e105	15.7	0
167	Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Diabetes Care</i> , 2016 , 39, 2042-2050	14.6	66
166	Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-nephrilysin inhibition compared with AT1 receptor blockade alone. <i>Clinical Science</i> , 2016 , 130, 1209-20	6.5	28
165	Reduced trigeminovascular cyclicality in patients with menstrually related migraine. <i>Neurology</i> , 2015 , 84, 125-31	6.5	25
164	Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. <i>European Respiratory Journal</i> , 2015 , 46, 1084-94	13.6	29
163	Effect of a stable Angiotensin-(1-7) analogue on progenitor cell recruitment and cardiovascular function post myocardial infarction. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	5
162	The renin-angiotensin system and its involvement in vascular disease. <i>European Journal of Pharmacology</i> , 2015 , 763, 3-14	5.3	72
161	The Role of the (Pro)renin Receptor in Hypertensive Disease. <i>American Journal of Hypertension</i> , 2015 , 28, 1187-96	2.3	29
160	Heart failure: New data do not SUPPORT triple RAAS blockade. <i>Nature Reviews Nephrology</i> , 2015 , 11, 260-2	14.9	8
159	Hypertension: renin-angiotensin-aldosterone system alterations. <i>Circulation Research</i> , 2015 , 116, 960-75	15.7	360
158	Expression and gene variation studies deny association of human HSD3B1 gene with aldosterone production or blood pressure. <i>American Journal of Hypertension</i> , 2015 , 28, 113-20	2.3	6

157	Angiotensin II type 2 receptor- and acetylcholine-mediated relaxation: essential contribution of female sex hormones and chromosomes. <i>Hypertension</i> , 2015 , 66, 396-402	8.5	29
156	Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. <i>Kidney International</i> , 2015 , 88, 109-20	9.9	32
155	Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. <i>Hypertension</i> , 2015 , 65, 1316-23	8.5	103
154	Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib. <i>Hypertension</i> , 2015 , 66, 543-9	8.5	30
153	Phosphodiesterase 1 regulation is a key mechanism in vascular aging. <i>Clinical Science</i> , 2015 , 129, 1061-75	6.5	39
152	The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. <i>Clinical Science</i> , 2014 , 126, 537-44	6.5	83
151	Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. <i>Hypertension</i> , 2014 , 63, 942-50	8.5	36
150	Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE?. <i>Cardiovascular Drugs and Therapy</i> , 2014 , 28, 335-45	3.9	10
149	Phosphodiesterase-5 activity exerts a coronary vasoconstrictor influence in awake swine that is mediated in part via an increase in endothelin production. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014 , 306, H918-27	5.2	6
148	The angiotensin II type 2 receptor for pain control. <i>Cell</i> , 2014 , 157, 1504-6	56.2	24
147	Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. <i>Hypertension</i> , 2014 , 64, 1282-9	8.5	65
146	Deterioration of kidney function by the (pro)renin receptor blocker handle region peptide in aliskiren-treated diabetic transgenic (mRen2)27 rats. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 306, F1179-89	4.3	18
145	Methylation of migraine-related genes in different tissues of the rat. <i>PLoS ONE</i> , 2014 , 9, e87616	3.7	17
144	Methodologic issues in the measurement of urinary renin. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 1163-7	6.9	6
143	Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism. <i>Journal of Hypertension</i> , 2014 , 32, 115-26	1.9	31
142	Neuron-specific (pro)renin receptor knockout prevents the development of salt-sensitive hypertension. <i>Hypertension</i> , 2014 , 63, 316-23	8.5	70
141	Combined renin inhibition/(pro)renin receptor blockade in diabetic retinopathy--a study in transgenic (mREN2)27 rats. <i>PLoS ONE</i> , 2014 , 9, e100954	3.7	20
140	The (pro)renin receptor. A decade of research: what have we learned?. <i>Pflugers Archiv European Journal of Physiology</i> , 2013 , 465, 87-97	4.6	50

139	Urinary markers of intrarenal renin-angiotensin system activity in vivo. <i>Current Hypertension Reports</i> , 2013 , 15, 81-8	4.7	25
138	(Pro)renin receptor is required for prorenin-dependent and -independent regulation of vacuolar H ⁺ -ATPase activity in MDCK.C11 collecting duct cells. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 305, F417-25	4.3	36
137	Key developments in renin-angiotensin-aldosterone system inhibition. <i>Nature Reviews Nephrology</i> , 2013 , 9, 26-36	14.9	75
136	Long-lasting physiological antagonism of calcitonin gene-related peptide towards endothelin-1 in rat mesenteric arteries and human coronary arteries. <i>European Journal of Pharmacology</i> , 2013 , 720, 303-9	5.3	8
135	Blunted coronary vasodilator response to uridine adenosine tetraphosphate in post-infarct remodeled myocardium is due to reduced P1 receptor activation. <i>Pharmacological Research</i> , 2013 , 77, 22-9	10.2	18
134	Uridine adenosine tetraphosphate is a novel vasodilator in the coronary microcirculation which acts through purinergic P1 but not P2 receptors. <i>Pharmacological Research</i> , 2013 , 67, 10-7	10.2	29
133	Analysis of the vascular responses in a murine model of polycystic ovary syndrome. <i>Journal of Endocrinology</i> , 2013 , 218, 205-13	4.7	11
132	Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. <i>Journal of Hypertension</i> , 2013 , 31, 444-54; discussion 454	1.9	47
131	New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin. <i>Hypertension</i> , 2013 , 61, 1075-82	8.5	12
130	How does the angiotensin II type 1 receptor compare to the type 2 receptor in blood pressure control?. <i>Journal of Hypertension</i> , 2013 , 31, 705-12	1.9	9
129	Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?. <i>Journal of Hypertension</i> , 2013 , 31, 1646-52	1.9	23
128	The (pro)renin receptor blocker handle region peptide upregulates endothelium-derived contractile factors in aliskiren-treated diabetic transgenic (mREN2)27 rats. <i>Journal of Hypertension</i> , 2013 , 31, 292-302	1.9	22
127	Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin. <i>Journal of Hypertension</i> , 2013 , 31, 713-9	1.9	13
126	Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. <i>Journal of Hypertension</i> , 2013 , 31, 404-13	1.9	17
125	A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c.3691+1G>A (IVS25+1G>A), causes a dramatic increase in circulating ACE through deletion of the transmembrane anchor. <i>PLoS ONE</i> , 2013 , 8, e59537	3.7	14
124	(Pro)renin and its receptors: pathophysiological implications. <i>Clinical Science</i> , 2012 , 123, 121-33	6.5	55
123	Nucleotide excision DNA repair is associated with age-related vascular dysfunction. <i>Circulation</i> , 2012 , 126, 468-78	16.7	104
122	Angiotensin II type 2 receptor agonists: where should they be applied?. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 501-13	5.9	40

121	Nitrite- and nitroxyl-induced relaxation in porcine coronary (micro-) arteries: underlying mechanisms and role as endothelium-derived hyperpolarizing factor(s). <i>Pharmacological Research</i> , 2012 , 66, 409-18	10.2	5
120	The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. <i>European Journal of Human Genetics</i> , 2012 , 20, 1071-7	5.3	23
119	AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 303, F1037-48	4.3	24
118	Plasma levels of prorenin and renin in blacks and whites: their relative abundance and associations with plasma aldosterone concentration. <i>American Journal of Hypertension</i> , 2012 , 25, 1030-4	2.3	22
117	Coronary microvascular dysfunction in a porcine model of early atherosclerosis and diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 302, H85-94	5.2	47
116	Renin and prorenin as biomarkers in hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2012 , 21, 508-14	3.5	10
115	Commentaries on viewpoint: epigenetic regulation of the ACE gene might be more relevant to endurance physiology than the I/D polymorphism. <i>Journal of Applied Physiology</i> , 2012 , 112, 1084-5	3.7	1
114	Differential diagnosis of preeclampsia: remember the soluble fms-like tyrosine kinase 1/placental growth factor ratio. <i>Hypertension</i> , 2012 , 60, 884-90	8.5	33
113	Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. <i>Hypertension</i> , 2012 , 59, 151-7	8.5	89
112	Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. <i>Hypertension</i> , 2012 , 60, 722-9	8.5	50
111	Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade. <i>PLoS ONE</i> , 2011 , 6, e23411	3.7	31
110	Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?. <i>Journal of Hypertension</i> , 2011 , 29, 2454-61	1.9	23
109	Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney. <i>Journal of Hypertension</i> , 2011 , 29, 2147-55	1.9	66
108	The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications. <i>Pharmacology & Therapeutics</i> , 2011 , 131, 50-60	13.9	40
107	Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. <i>Cephalalgia</i> , 2011 , 31, 181-9	6.1	50
106	Renin- and prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur?. <i>Hypertension</i> , 2011 , 58, 1111-9	8.5	53
105	Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats. <i>Hypertension</i> , 2011 , 57, 852-8	8.5	33
104	The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. <i>Hypertension</i> , 2011 , 58, 295-302	8.5	99

103	Daily red wine consumption improves vascular function by a soluble guanylyl cyclase-dependent pathway. <i>American Journal of Hypertension</i> , 2011 , 24, 162-8	2.3	24
102	The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?. <i>Hypertension Research</i> , 2010 , 33, 4-10	4.7	33
101	Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. <i>Hypertension</i> , 2010 , 56, 675-81	8.5	202
100	Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts. <i>Cardiovascular Research</i> , 2010 , 86, 401-9	9.9	55
99	Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. <i>European Heart Journal</i> , 2010 , 31, 1854-64	9.5	56
98	Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. <i>Hypertension</i> , 2010 , 55, 516-22	8.5	51
97	Cardiac angiotensin II: does it have a function?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 299, H1304-6	5.2	9
96	Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors?. <i>Journal of Hypertension</i> , 2010 , 28, 1044-53	1.9	32
95	Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2010 , 28, 2145-55	1.9	45
94	Mast cell degranulation mediates bronchoconstriction via serotonin and not via renin release. <i>European Journal of Pharmacology</i> , 2010 , 640, 185-9	5.3	13
93	Specific coronary drug-eluting stents interfere with distal microvascular function after single stent implantation in pigs. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 723-30	5	12
92	Does prorenin exert angiotensin-independent effects in vivo?. <i>Hypertension</i> , 2009 , 54, 1218-20	8.5	3
91	Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. <i>Clinical Chemistry</i> , 2009 , 55, 867-77	5.5	145
90	Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. <i>Diabetes Care</i> , 2009 , 32, 1873-9	14.6	124
89	(Pro)renin receptor and vacuolar H ⁺ -ATPase. <i>Hypertension</i> , 2009 , 54, 219-21	8.5	15
88	Cardiac Renin levels are not influenced by the amount of resident mast cells. <i>Hypertension</i> , 2009 , 54, 315-21	8.5	20
87	Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-beta1 axis?. <i>Molecular and Cellular Endocrinology</i> , 2009 , 302, 213-8	4.4	21
86	Renal plasma flow: glomerular filtration rate relationships in man during direct renin inhibition with aliskiren. <i>Journal of the American Society of Hypertension</i> , 2009 , 3, 315-20		10

85	Aldosterone-receptor antagonism in hypertension. <i>Journal of Hypertension</i> , 2009 , 27, 680-91	1.9	66
84	Light-induced vs. bradykinin-induced relaxation of coronary arteries: do S-nitrosothiols act as endothelium-derived hyperpolarizing factors?. <i>Journal of Hypertension</i> , 2009 , 27, 1631-40	1.9	27
83	(Pro)renin receptors: are they biologically relevant?. <i>Current Opinion in Nephrology and Hypertension</i> , 2009 , 18, 74-8	3.5	23
82	The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?. <i>European Heart Journal</i> , 2009 , 30, 805-12	9.5	81
81	Aldosterone synthase inhibitors: pharmacological and clinical aspects. <i>Current Opinion in Investigational Drugs</i> , 2009 , 10, 319-26		13
80	Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. <i>Experimental Physiology</i> , 2008 , 93, 557-63	2.4	75
79	The (pro)renin receptor: a new addition to the renin-angiotensin system?. <i>European Journal of Pharmacology</i> , 2008 , 585, 320-4	5.3	14
78	Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT ₂ receptor?. <i>European Journal of Pharmacology</i> , 2008 , 588, 286-93	5.3	37
77	The renin rise with aliskiren: it's simply stoichiometry. <i>Hypertension</i> , 2008 , 51, e27-8; author reply e29	8.5	23
76	Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 1151-7	9.4	82
75	Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. <i>Hypertension</i> , 2008 , 51, 682-8	8.5	186
74	Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. <i>Hypertension</i> , 2008 , 52, 1076-83	8.5	70
73	Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors. <i>FASEB Journal</i> , 2008 , 22, 3068-77	0.9	41
72	A twofold genetic increase of ACE expression has no effect on the development of spontaneous hypertension. <i>American Journal of Hypertension</i> , 2008 , 21, 200-5	2.3	3
71	Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. <i>Circulation</i> , 2008 , 117, 3199-205	16.7	141
70	Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. <i>Hypertension</i> , 2008 , 52, 130-6	8.5	238
69	Effect of (pro)renin receptor inhibition by a decoy peptide on renal damage in the clipped kidney of Goldblatt rats. <i>Kidney International</i> , 2008 , 74, 823-4	9.9	19
68	Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype. <i>Journal of Hypertension</i> , 2008 , 26, 706-13	1.9	13

67	Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. <i>Current Opinion in Cardiology</i> , 2008 , 23, 296-301	2.1	10
66	Prorenin anno 2008. <i>Journal of Molecular Medicine</i> , 2008 , 86, 655-8	5.5	17
65	Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin. <i>Current Hypertension Reports</i> , 2008 , 10, 112-8	4.7	57
64	The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1166-74	15.1	77
63	ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? 2007 , 113, 607-18		67
62	Aliskiren: the first direct renin inhibitor for hypertension. <i>Current Cardiology Reports</i> , 2007 , 9, 470-6	4.2	11
61	Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. <i>Journal of Hypertension</i> , 2007 , 25, 2441-53	1.9	168
60	Novel drugs targeting hypertension: renin inhibitors. <i>Journal of Cardiovascular Pharmacology</i> , 2007 , 50, 105-11	3.1	23
59	Why are mineralocorticoid receptor antagonists cardioprotective?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006 , 374, 153-62	3.4	42
58	Elevated blood pressure and heart rate in human renin receptor transgenic rats. <i>Hypertension</i> , 2006 , 47, 552-6	8.5	183
57	Letter by Krop et al regarding article, "Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium". <i>Circulation</i> , 2006 , 114, e556; author reply e557	16.7	
56	Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. <i>Hypertension</i> , 2006 , 48, 564-71	8.5	209
55	Cardiac aldosterone in subjects with hypertrophic cardiomyopathy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006 , 7, 225-30	3	12
54	Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?. <i>Hypertension</i> , 2006 , 47, 665-70	8.5	34
53	Prorenin Uptake in the Heart 2006 , 31-45		
52	AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation. <i>British Journal of Pharmacology</i> , 2006 , 148, 452-8	8.6	37
51	Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?. <i>FASEB Journal</i> , 2006 , 20, A342	0.9	
50	Renin, prorenin and the putative (pro)renin receptor. <i>Hypertension</i> , 2005 , 46, 1069-76	8.5	188

49	Adrenal angiotensin: origin and site of generation. <i>American Journal of Hypertension</i> , 2005 , 18, 1104-10	2.3	14
48	Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. <i>Hypertension</i> , 2005 , 46, 569-76	8.5	200
47	Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?. <i>British Journal of Pharmacology</i> , 2005 , 145, 664-71	8.6	36
46	Angiotensin II type 2 receptor-mediated vasodilation. Focus on bradykinin, NO and endothelium-derived hyperpolarizing factor(s). <i>Vascular Pharmacology</i> , 2005 , 42, 109-18	5.9	39
45	Is angiotensin II made inside or outside of the cell?. <i>Current Hypertension Reports</i> , 2005 , 7, 124-7	4.7	24
44	Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. <i>Hypertension</i> , 2005 , 46, 701-6	8.5	68
43	Renin, prorenin and the putative (pro)renin receptor. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005 , 6, 163-5	3	19
42	Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. <i>Circulation</i> , 2005 , 112, 364-74	16.7	147
41	Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. <i>Hypertension</i> , 2005 , 45, 120-5	8.5	42
40	Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. <i>Circulation</i> , 2004 , 109, 2296-301	16.7	161
39	Mediators of bradykinin-induced vasorelaxation in human coronary microarteries. <i>Hypertension</i> , 2004 , 43, 488-92	8.5	47
38	Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as EDHF?. <i>British Journal of Pharmacology</i> , 2004 , 142, 125-35	8.6	59
37	L-S-nitrosothiols: endothelium-derived hyperpolarizing factors in porcine coronary arteries?. <i>Journal of Hypertension</i> , 2004 , 22, 1927-36	1.9	40
36	ACE-versus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 251-6	9.4	49
35	Local renin-angiotensin systems: the unanswered questions. <i>International Journal of Biochemistry and Cell Biology</i> , 2003 , 35, 759-68	5.6	96
34	Vasoconstriction is determined by interstitial rather than circulating angiotensin II. <i>British Journal of Pharmacology</i> , 2002 , 135, 275-83	8.6	37
33	Bradykinin potentiation by ACE inhibitors: a matter of metabolism. <i>British Journal of Pharmacology</i> , 2002 , 137, 276-84	8.6	47
32	Prorenin-induced myocyte proliferation: no role for intracellular angiotensin II. <i>Hypertension</i> , 2002 , 39, 573-7	8.5	87

31	Transendothelial transport of renin-angiotensin system components. <i>Journal of Hypertension</i> , 2002 , 20, 2029-37	1.9	16
30	Prorenin uptake in the heart: a prerequisite for local angiotensin generation?. <i>Journal of Molecular and Cellular Cardiology</i> , 2002 , 34, 1463-72	5.8	23
29	Cardiac angiotensin II: an intracrine hormone?. <i>American Journal of Hypertension</i> , 2002 , 15, 1109-16	2.3	16
28	Prorenin accumulation and activation in human endothelial cells: importance of mannose 6-phosphate receptors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001 , 21, 911-6	9.4	69
27	Cardiomyocytes bind and activate native human prorenin : role of soluble mannose 6-phosphate receptors. <i>Hypertension</i> , 2001 , 37, 710-5	8.5	64
26	High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001 , 280, H1706-15	5.2	60
25	AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001 , 281, H2590-6	5.2	31
24	Subcellular localization of angiotensin II in kidney and adrenal. <i>Journal of Hypertension</i> , 2001 , 19, 583-9	1.9	63
23	Angiotensin converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of the isolated perfused rat heart. <i>Journal of Hypertension</i> , 2001 , 19, 959-65	1.9	25
22	Negative inotropic effect of bradykinin in porcine isolated atrial trabeculae: role of nitric oxide. <i>Journal of Hypertension</i> , 2001 , 19, 1289-93	1.9	9
21	Albuminuria in mice after injection of antibodies against aminopeptidase A: role of angiotensin II. <i>Journal of the American Society of Nephrology: JASN</i> , 2001 , 12, 2711-2720	12.7	11
20	L-NAME-resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition. <i>British Journal of Pharmacology</i> , 2000 , 131, 195-202	8.6	46
19	Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. <i>Hypertension</i> , 2000 , 35, 764-8	8.5	51
18	Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. <i>Circulation</i> , 2000 , 102, 1556-63	16.7	118
17	The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 484-90	3.1	44
16	Cardiac interstitial fluid levels of angiotensin I and II in the pig. <i>Journal of Hypertension</i> , 1999 , 17, 1885-91	1.9	41
15	Angiotensin I to angiotensin II conversion in the human forearm and leg. Effect of the angiotensin converting enzyme gene insertion/deletion polymorphism. <i>Journal of Hypertension</i> , 1999 , 17, 1867-72	1.9	28
14	Uptake and proteolytic activation of prorenin by cultured human endothelial cells. <i>Journal of Hypertension</i> , 1999 , 17, 621-9	1.9	51

13	17th Scientific Meeting of the International Society of Hypertension. <i>Expert Opinion on Investigational Drugs</i> , 1998 , 7, 1335-40	5.9	
12	70th Scientific Sessions of the American Heart Association. <i>Expert Opinion on Investigational Drugs</i> , 1998 , 7, 117-20	5.9	1
11	AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. <i>Hypertension</i> , 1998 , 32, 825-30	8.5	105
10	Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. <i>Circulation</i> , 1998 , 98, 73-81	16.7	181
9	Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. <i>Journal of Hypertension</i> , 1998 , 16, 1879-83	1.9	69
8	Bradykinin-induced release of nitric oxide by the isolated perfused rat heart: importance of preformed pools of nitric oxide-containing factors. <i>Journal of Hypertension</i> , 1998 , 16, 239-44	1.9	26
7	Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. <i>Journal of Hypertension</i> , 1998 , 16, 853-62	1.9	181
6	Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. <i>Circulation</i> , 1997 , 96, 220-6	16.7	97
5	Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. <i>Hypertension</i> , 1997 , 29, 1240-51	8.5	92
4	Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. <i>Hypertension</i> , 1997 , 30, 42-9	8.5	127
3	Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. <i>Hypertension</i> , 1997 , 30, 1389-96	8.5	93
2	Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. <i>British Journal of Ophthalmology</i> , 1996 , 80, 159-63	5.5	185
1	Local renin-angiotensin systems. <i>Molecular and Cellular Biochemistry</i> , 1996 , 157, 211-6	4.2	71